EPIRUS Biopharmaceuticals Financials

EPIRUS Biopharmaceutica Stock Summary

EPIRUS Biopharmaceutica competes with Genenta Science, Molecular Partners, Mineralys Therapeutics,, AN2 Therapeutics, and Pharvaris. EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts. EPIRUS BIOPHARMACEUTICA operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 73 people.

EPIRUS Biopharmaceutica Key Financial Ratios

EPIRUS Biopharmaceutica's financial ratios allow both analysts and investors to convert raw data from EPIRUS Biopharmaceutica's financial statements into concise, actionable information that can be used to evaluate the performance of EPIRUS Biopharmaceutica over time and compare it to other companies across industries.

EPIRUS Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining EPIRUS Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare EPIRUS Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across EPIRUS Biopharmaceutica competition to find correlations between indicators driving EPIRUS Biopharmaceutica's intrinsic value. More Info.EPIRUS Biopharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the EPIRUS Biopharmaceutica's earnings, one of the primary drivers of an investment's value.

EPIRUS Biopharmaceutica Market Pulse

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

If you are still planning to invest in EPIRUS Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EPIRUS Biopharmaceutica's history and understand the potential risks before investing.